HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects

• Published in: Nature medicine Vol. 16; no. 4; pp. 460 - 465
• Main Authors: J Buzón, Maria, Massanella, Marta, Llibre, Josep M, Esteve, Anna, Dahl, Viktor, Puertas, Maria C, Gatell, Josep M, Domingo, Pere, Paredes, Roger, Sharkey, Mark, Palmer, Sarah, Stevenson, Mario, Clotet, Bonaventura, Blanco, Julià, Martinez-Picado, Javier
• Format: Journal Article
• Language: English
• Published: New York Nature Publishing Group US 01.04.2010; Nature Publishing Group
• Subjects: 631/326/596/1296; 631/92/436/2388; 692/699/249/1570/1901; Antiretroviral agents; Antiretroviral Therapy, Highly Active; Antiviral drugs; Biomedical and Life Sciences; Biomedicine; Cancer Research; Deoxyribonucleic acid; DNA; DNA, Complementary - genetics; DNA, Viral - genetics; Dosage and administration; Drug therapy; Health aspects; Highly active antiretroviral therapy; HIV; HIV infection; HIV Infections - drug therapy; HIV Infections - immunology; HIV Infections - virology; HIV Integrase Inhibitors - pharmacology; HIV Integrase Inhibitors - therapeutic use; HIV Long Terminal Repeat - drug effects; HIV Long Terminal Repeat - genetics; HIV-1 - drug effects; HIV-1 - immunology; HIV-1 - physiology; Human immunodeficiency virus; Human immunodeficiency virus 1; Humans; Immunology; Infectious Diseases; Inhibitor drugs; letter; Metabolic Diseases; Molecular Medicine; Neurosciences; Polymerase Chain Reaction; Pyrrolidinones - pharmacology; Pyrrolidinones - therapeutic use; Raltegravir; Raltegravir Potassium; Virus Integration - drug effects; Virus Replication - drug effects; Virus Replication - physiology; United States

Despite highly active antiretroviral therapy, active replication persists and drives immune activation in some individuals with HIV. This activation is higher if therapy is intensified by additional antiretroviral drugs ( pages 373–374 ). Highly active antiretroviral therapy (HAART) results in poten...